Neoadjuvant Docetaxel, Epirubicin, and Cyclophosphamide With or Without Metformin in Patients With Breast Cancer With Metabolic Abnormality
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial
Breast Cancer Res Treat 2022 Dec 16;[EPub Ahead of Print], J Huang, Y Tong, J Hong, O Huang, J Wu, J He, W Chen, Y Li, X Chen, K ShenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.